The effect of hesperidin use on the clinical condition of patients with the new coronavirus

Phase 3

• Conditions: Covid-19.; COVID-19, virus not identified; U07.02

• Registration Number: IRCT20150725023332N5
• Lead Sponsor: Shahid Beheshti University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 26 April 2021

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Patients with new coronavirus who hospitalized in the intensive care unit

Exclusion Criteria

Patients with intubation conditions
History of severe liver disease
History of severe renal disease
Patient dissatisfaction to participate in the project
Age over 65 and under 18 years

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
actate dehydrogenase. Timepoint: Before prescribing of Hesperidin and 5 days after taking it. Method of measurement: Lactate dehydrogenase testing by blood sampling.;Cratinin. Timepoint: Before prescribing of Hesperidin and 5 days after taking it. Method of measurement: Testing for creatinine in the serum.;BUN. Timepoint: Before prescribing of Hesperidin and 5 days after taking it. Method of measurement: Blood urea test.